Arthur Cox and Goodwin represented Repligen Corporation on the transaction.

Repligen, a life sciences company focused on bioprocessing technology leadership, agreed to acquire ARTeSYN Biosolutions for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock.

The ARTeSYN deal, combined with the recent acquisitions of Engineered Molding Technologies (EMT) and Non-Metallic Solutions (NMS), strengthens Repligen’s capabilities in single-use systems and associated integrated flow path assemblies, according to the company.

ARTeSYN provides single-use systems for chromatography, filtration, continuous manufacturing, and media/buffer prep workflows. In addition, the company has integrated flow path assemblies utilizing EMT’s silicone extrusion and molding technology, to deliver highly differentiated, low hold-up volume systems that minimize product loss during processing.

The Arthur Cox team was led by Christopher McLaughlin (Picture, Corporate and M&A) and included Dannie Hanna, Sinéad McDonagh and Niamh Gunning (Corporate and M&A), Cian Beecher and Emma Dunne (Employment), Imelda Shiels (Finance), Fintan Clancy (Tax), Deirdre Sheehan (Real Estate), Michael Shovlin and Katie Lawless (Pensions) and Colm Maguire (Technology and Innovation).

Involved fees earner: Cian Beecher – Arthur Cox; Fintan Clancy – Arthur Cox; Emma Dunne – Arthur Cox; Niamh Gunning – Arthur Cox; Dannie Hanna – Arthur Cox; Katie Lawless – Arthur Cox; Colm Maguire – Arthur Cox; Sinéad McDonagh – Arthur Cox; Christopher McLaughlin – Arthur Cox; Deirdre Sheehan – Arthur Cox; Imelda Shiels – Arthur Cox; Michael Shovlin – Arthur Cox;

Law Firms: Arthur Cox;

Clients: Repligen Corporation;